PLX 100

Drug Profile

PLX 100

Alternative Names: PLX100

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polaryx Therapeutics
  • Class Acids; Small molecules
  • Mechanism of Action Tripeptidyl-peptidase 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neuronal ceroid lipofuscinosis

Most Recent Events

  • 09 May 2017 PLX 100 is available for licensing as of 09 May 2017. (Polaryx Therapeutics pipeline, May 2017)
  • 09 May 2017 Preclinical trials in Neuronal ceroid lipofuscinosis in USA (PO) before May 2017 (Polaryx Therapeutics pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top